Day: November 13, 2025

Entered into an exclusive license agreement with Dynavax for the Company’s COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment of approximately 5,400 participants in COVID-19 Phase 2b trial with topline data expected in late 2026; Topline data from 400-person sentinel cohort anticipated in the first quarter of 2026 Reported additional supportive data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, demonstrating potential for improved protection against infection; Company continues to explore partnership opportunities Cash, cash equivalents and investments of $28.8 million as of September 30, 2025; Current runway extended into second quarter of 2027 Conference call today at 4:30 p.m. ET Live stockholder fireside...

Business highlights include:Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance Registry New clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollment Strengthened the balance sheet, raising $12.4 million to fund future operations Webcast call today at 4:30 p.m. Eastern TimeDENVER, Nov. 13, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today financial results for the three months ended September 30, 2025, and provided business updates...

Third Quarter 2025 Revenues Increased 41% to $7.4 Million, Driving Net Income of $0.8 Million CORSICANA, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) — Birchtech Corp. (TSX: BCHT) (OTCQB: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today reported financial results for the third quarter ended September 30, 2025. Key Third Quarter 2025 & Subsequent Operational HighlightsPending final judgment following the $57 million patent infringement verdict, from which the Company’s counsel requested $160 million inclusive of enhancements, interest and legal fees. Four key air business licensing agreements secured, with the potential to transition into long-term product supply agreements:A non-exclusive licensing agreement with a large regional coal-fired...

AIRJ Expands Strategic Partnerships and Advances Productization of AirJoule™ Systems Ahead of Commercial Deployments in 2026 RONAN, Mont., Nov. 13, 2025 (GLOBE NEWSWIRE) — AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or “AIRJ”), a leading technology platform that unleashes the power of water from air, today announced its third quarter 2025 results and provided a business update highlighting progress toward near-term commercialization. “AirJoule Technologies is addressing emerging opportunities driven by powerful macro trends that are fundamentally reshaping global water and energy markets,” said Matt Jore, Chief Executive Officer of AirJoule Technologies. “Water scarcity is intensifying across key industrial and population centers. Data center expansion is driving unprecedented demand for sustainable...

– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 –  – Potential NDA submission for schizophrenia indication targeted for Q2 2026 – – European patent granted covering use of brilaroxazine for the treatment of pulmonary fibrosis adds to existing patent protection in key global markets – CUPERTINO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2025 and summarized recent business highlights. “With the comprehensive clinical and non-clinical...

September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or the “Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and provided a business update to shareholders for the third quarter ended September 30, 2025. “We continue to make strong progress both in our commercial and clinical activities,” said Shaun Bagai, CEO of RenovoRx. “On the commercial side, we are encouraged by the continued RenovoCath clinical adoption we are seeing in the field. Year-to-date revenue,...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated with Prader-Willi Syndrome (PWS) New preclinical data presented at ObesityWeek 2025 demonstrates the potential of ARD-201 in enhanced glucose control, along with preservation of lean body mass, underscoring its opportunity in addressing key challenges in today’s obesity treatment landscape Oral ARD-201 shows potential for weight management after GLP-1RA discontinuation, supported by new promising preclinical results and ARD-101 clinical data $126.4 million in cash, cash equivalents, and short-term investments as of September 30, 2025, supports projected operations into 2027 SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Aardvark...

Launches New High-Performing XTM Mining Products to Support Revenue Growth in Q4 2025 Initiates ETH Staking with FalconX with Initial 1,000 ETH in Place Acquisition of Proof-of-Stake Platform to Advance Cryptocurrency Staking Business SINGAPORE, Nov. 13, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company engaged in the provision of altcoin mining products, strategic acquisition and holding of Ethereum-based cryptocurrencies, and active development of innovative Web3 applications, today announced its unaudited financial results for the third quarter (“Q3 2025”) and nine months (“9M 2025”) ended September 30, 2025. Q3 2025 FINANCIAL HIGHLIGHTSRevenue: Revenue was RMB9.1 million (US$1.3 million), compared to RMB60.3 million for the same period of 2024. Income/(Loss) from Operations:...

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its third fiscal quarter ended September 30, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange...